Utah Medical Products, Inc. (UTMD) reported its fourth-quarter earnings for 2025 on December 31, revealing a 6.3% drop in earnings per share (EPS) to 80.2 cents, down from 85.7 cents year-over-year. The company’s total revenue for the quarter was $9 million, a 1.2% decline from $9.2 million in the same quarter last year. Net income fell 11.6% to $2.6 million, down from $2.9 million, highlighting the challenges of operating expenses and a decrease in U.S. sales.
For the full year, UTMD reported sales of $38.5 million, a 5.8% decline from $40.9 million in 2024, with net income dropping 18.7% to $11.3 million. The company maintained a gross profit margin of 57.1%, down from 59% a year earlier, reflecting ongoing pressures from raw materials and increased operational costs. Despite these challenges, UTMD ended the year with $85.8 million in cash and investments and no debt.
Management anticipates that U.S. sales in 2026 will remain impacted, with expected zero sales to both PendoTECH and a Chinese distributor, and plans to offset this by introducing new products and enhancing Filshie sales domestically and internationally.
